Tofacitinib for ulcerative colitis: A promising treatment option

Zong-Qiang Han; Li-Na Wen

doi:10.3748/wjg.v30.i40.4386

Tofacitinib for ulcerative colitis: A promising treatment option

World J Gastroenterol. 2024 Oct 28;30(40):4386-4392. doi: 10.3748/wjg.v30.i40.4386.

Authors

Zong-Qiang Han¹, Li-Na Wen²

Affiliations

¹ Department of Laboratory Medicine, Beijing Xiaotangshan Hospital, Beijing 102211, China.
² Department of Clinical Nutrition, Beijing Shijitan Hospital, Capital Medical University, Beijing 100038, China. [email protected].

Abstract

A single center retrospective clinical study revealed the efficacy and safety of tofacitinib in the treatment of ulcerative colitis (UC). This study has clinical reference value but also has some limitations. Previous studies, including this clinical trial, have shown that tofacitinib could be a promising treatment option for UC, but further clinical research is required to prove this point.

Keywords: Clinical trials; Efficacy; Safety; Tofacitinib; Ulcerative colitis.

Publication types

Letter

MeSH terms

Adult
Colitis, Ulcerative* / diagnosis
Colitis, Ulcerative* / drug therapy
Female
Humans
Male
Middle Aged
Piperidines* / adverse effects
Piperidines* / therapeutic use
Protein Kinase Inhibitors* / adverse effects
Protein Kinase Inhibitors* / therapeutic use
Pyrimidines* / adverse effects
Pyrimidines* / therapeutic use
Pyrroles* / therapeutic use
Retrospective Studies
Treatment Outcome
Young Adult

Substances

tofacitinib
Piperidines
Pyrimidines
Protein Kinase Inhibitors
Pyrroles